Upregulation of Interferon-α Receptor Expression in Hydroxyurea-Treated Leukemia Cell Lines

Journal of Investigative Medicine

Volumn 45, Issue 4, 1997, Pages 160-167

  Tamura, Tomohiko ^a   Matsuzaki, Michio ^a   Harada, Hisashi ^b   Ogawa, Koji ^a   Mohri, Hiroshi ^a   Okubo, Takao ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Daudi cells; Hydroxyurea; Interferon ; Interferon receptor; K562 cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; HYDROXYUREA; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; IRF1 PROTEIN, HUMAN; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYUREA; INTERFERON REGULATORY FACTOR-1; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PHOSPHOPROTEINS; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031110381     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gutterman JU. The role of interferons in the treatment of hematologic malignancies. Semin Hematol 1988;25:3-8.
2. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation on human alpha interferon in chronic myelogeneous leukemia. Blood 1987;69:1280-8.
3. Yoffe G, Blick M, Kantarjian HM, Spitzer G, Gutterman J, Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myelogeneous leukemia. Blood 1987;69:961-3.
4. Freund M, Wussow PV, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, Leblanc S, Fonatsch C, Deicher H, Poliwoda H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: Dose dependency of response and frequency of neutralizing anti-interferon-antibodies during interferon therapy. Br J Haematol 1989;72: 350-6.
5. Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heinpel H. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelogeneous leukemia. Blutallkohol 1989;58;275-8.
6. Asano S, Ogura H, Tani K, Inoue T, Tojo A, Ozawa K. Several new approaches to improvement of alpha interferon therapy in chronic myelogeneous leukemia. Eur J Cancer 1991;27 (4 Suppl):21-5.
7. Kantarjian HM, Keating MT, Estey EH, O'Brein S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogeneous leukemia with interferon-α and low dose cytarabine. J Clin Oncol 1992;10:772-8.
8. Pellegrini S, Schindler C. Early events in signaling by interferons. Trends Biochem Sci 1993;18:338-42.
9. Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vitro sensitivity and resistance of chronic myelogeneous leukemia cells to α-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res 1986;46:4848-52.
10. Pfeffer LM, Donner DB. The down-regulation of α-interferon receptors in human lymphoblastoid cells: relation to cellular responsiveness to the antiproliferative action of α-interferon. Cancer Res 1990;50:2654-7.
11. Hannigan G, Williams BRG. Transcriptional regulation of interferon-responsive genes is closely linked to interferon receptor occupacy. EMBO J 1986;5:1607-13.
12. Fracker DJ, Speck JC. Protein and plasma membrane iodinations with sparingly soluble chloramide 1,3,4,6 tetrachloro 3a,6a diphenylglycouril. Biochem Biophys Res Commun 1978;35:1143-8.
13. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-72.
14. Foa P, Maiolo AT, Lombardi L, Villa L, Polli EE. Inhibition of proliferation of human leukaemic cell lines by deferoxamine. Scand J Haematol 1986;36:107-10.
15. Barlogie B, Drewinko B, Johnston DA, Bucher T, Hauss WT, Freireich EJ. Pulse cytometric analysis of synchronized cells in vitro. Cancer Res 1976;36:1176-81.
16. Shibuya H, Yoneyama M, Nakamura Y, Harada H, Hatakeyama M, Minamoto S, Kono T, Doi T, White R, Taniguchi T. The human interleukin-2 receptor β-chain gene: genomic organizatioin, promoter analysis and chromosomal assignment. Nucleic Acids Res 1990;18:3697-703.
17. Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, Taniguchi T. Absence of type I IFN system in EC cells: Transcriptional activator (IRF-1) and suppresser (IRF-2) genes are developmentally regulated. Cell 1990;63:303-12.
18. Maruyama M, Fujita T, Taniguchi T. Sequence of a cDNA coding for human IRF-1. Nucleic Acids Res 1989;17:3292.
19. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 1988;54:903-13.
20. Walker MM, Wanda PE. Immunochemical detection of cell cycle synchronization in a human erythroleukemic cell line, K562. J Histochem Cytochem 1987;35:1143-8.
21. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58:729-39.
22. Kirchhoff S, Schaper F, Hauser H. Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. Nucleic Acids Res 1993;21:2881-9.
23. Kimura K. A cooperative phase I-II study of HLBI in patients with malignant tumors. Gan To Kagaku Royoho 1984;11:1324-31.
24. Donehower RC. Hyroxyurea. In: Chanber P, ed. Pharmacological principles of cancer treatment. Philadelphia: Saunders, 1990:225-33.
25. Cress AE, Gerner EW. Hydroxyurea inhibits ODC induction, but not the G1 to S-phase transition. Biochem Biophys Res Commun 1979;87:773-80.
26. Horoszewicz JS, Leong SS, Carter WA. Noncycling tumor cells are sensitive targets for the antiproliferative activvity of human interferon. Science 1979;206:1091-3.
27. Bosch JVd, Zirvi KA. Growth state-specific responsiveness of primary cultures of a nude mouse-xenografted human colon carcinoma to 4′-deoxyoxorubicin and a crude human leukocyte alpha-interferon preparation. Cancer Res 1982;42:3789-92.
28. Carver DH, Marcus PI. Enhanced interferon production from chick embryo cells aged in vitro. Virology 1967;32:247-57.
29. Rossman TG, Vilcek J. Influence of the rate of cell growth and cell density on interferon action in chick embryo cells. J Virol 1969;4:7-11.
30. Carter WA. Interferon: enhanced synthesis and action in mouse and human cells under suboptimal growth conditions. Johns Hopkins Med 1972;130:166-73.
31. Dilollo DL, Beilharz MW, Lai MC, Minchin RF. Difluoromethylornithine prevents the down-regulation of type I interferon receptors: a possible mechamism for a synergistic antiproliferative effect. Mol Pharmacol 1990;38:451-4.
32. Martin JHJ, McKibben BM, Lynch M, Berg HWvd. Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells, Eur J Cancer 1991;27:143-6.
33. 125I-labeled interferon-βser to cellular receptors during growth of human renal and bladder cells in vitro. Cancer Res 1987;47:4582-9.
34. Thomopoulis P, Roth J, Lovelace E, Pastan E. Insulin receptors in normal and transformed fibroblast: relationship to growth and transformation. Cell 1976;8:417-23.
35. Bhargava G, Rifas L, Makman MH. Presence of epidermal growth factor receptors and influence of epidermal growth factor on proliferation and aging in cultured smooth muscle cells. J Cell Physiol 1979;100:365-74.
36. Revoltella R, Bertolini L, Pediconi M. Unmasking of nerve growth factor membrane specific binding sites in synchronized murine C1300 neuroblastoma cells. Exp Cell Res 1974;85:88-94.
37. Shibata K, Nishimura J, Takahira H, Nawata H. α-interferon reduces in vivo phosphorylation of p210bcr/abl protein during hemin-induced erythroid differentiation of K-562 cells. Exp Hematol 1991;19:161-5.